Ceftizoxime
A third-generation parenteral cephalosporin antibiotic with broad-spectrum activity against gram-negative bacteria and anaerobes, used for serious urinary, respiratory, and intra-abdominal infections. It has greater anaerobic coverage compared to many other third-generation cephalosporins. Renal impairment requires dosage adjustment due to its primarily renal elimination.
Peso molecular
383,4000 g/mol
LogP
0,00
TPSA
201,00 Ų
Regla de cinco de Lipinski
Cumple
Mecanismo de acción
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=CCS[C@H]12)c1csc(N)n1
InChI
InChI=1S/C13H13N5O5S2/c1-23-17-7(5-4-25-13(14)15-5)9(19)16-8-10(20)18-6(12(21)22)2-3-24-11(8)18/h2,4,8,11H,3H2,1H3,(H2,14,15)(H,16,19)(H,21,22)/b17-7-/t8-,11-/m1/s1
Molecular Formula
C13H13N5O5S2
HBD / HBA
3 / 10
Enlaces Rotables
5
Átomos Pesados
25
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A third-generation parenteral cephalosporin antibiotic with broad-spectrum activity against gram-negative bacteria and anaerobes, used for serious urinary, respiratory, and intra-abdominal infections. It has greater anaerobic coverage compared to many other third-generation cephalosporins. Renal impairment requires dosage adjustment due to its primarily renal elimination.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Ceftizoxime is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL528. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6533629. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ceftizoxime"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ceftizoxime/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ceftizoxime/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ceftizoxime/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ceftizoxime"></drugfyi-drug>